New developments in the pathogenesis of systemic sclerosis

Autoimmunity

Volumn 38, Issue 2, 2005, Pages 113-116

  Sakkas, Lazaros I ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

B cells; Fibrosis; Systemic sclerosis; T cells; Vasculopathy

Indexed keywords

AUTOANTIBODY; CD19 ANTIGEN; CD20 ANTIBODY; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; ENDOTHELIAL CELL ANTIBODY; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 4; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR; T LYMPHOCYTE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; LYMPHOCYTIC INFILTRATION; NONHUMAN; PATHOGENESIS; SKIN DEFECT; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; TREATMENT PLANNING; VASCULAR DISEASE;

ANIMALS; ANTIGENS, CD19; AUTOANTIBODIES; B-LYMPHOCYTES; BLOOD VESSELS; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; SCLERODERMA, SYSTEMIC; SKIN;

EID: 21044454608     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.1080/16066350500095415     Document Type: Article

References (48)

1. Hayes MD, Lacey JV, Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-2255.
2. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi J-T, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK. Systemic and cell-cycle specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003;100:12319-12324.
3. Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 2004;50:1721-1733.
4. Massague J. Transforming growth factor-β family. Annu Rev Cell Biol 1990;6:597-641.
5. Nabel EG, Shum L, Pompili VJ, Yang Z, San H, Shu HB, Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ. Direct transfer of transforming growth factor β1 gene into arteries stimulates fibrocellular hyperlpasia. Proc Natl Acad Sci USA 1993;90:10759-10763.
6. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents upregulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001;44:474-480.
7. Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, Masuda K, Wang XJ, DiPietro LA, Varga J. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004;165:203-217.
8. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T. Smurfl interacts with transforming growth factor-b type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001;276:12477-12480.
9. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGFβ signaling in scleroderma fibroblasts. J Clin Invest 2004; 113:253-264.
10. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479-1485.
11. Mueller R, Krahl T, Sarvetnick N. Tissue-specific expression of interleukin-4 induces extracellular matrix accumulation and extravasation of B cells. Lab Invest 1997;76:117-128.
12. Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H. Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. The IgE allotype is an important marker of graft-versus-host disease. J Immunol 1995;154:2687-2696.
13. Gay S, Jones RE, Jr, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J Invest Dermatol 1989;92:301-303.
14. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779-17784.
15. Shi-wen X, Pennington D, Holmes A, Leask A, Bradham D, Beauchamp JR, Fonseca L, du Bois RM, Martin GR, Black CM, Abraham DJ. Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000;259:213-224.
16. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S, Gay RE, Michel BA, Bruhlmann P, Muller-Ladner U, Gay S, Matucci-Cerinic M. Angiogenic and angiostatic factors in systemic sclerosis: Increased levels of vascular endothelial growth factor are a feature of earliest disease stages and are associated with absence of fingertips ulcers. Arthritis Res 2002;4:R11.
17. Worda M, Sgonc R, Dietrich H, Niedergger H, Sundick RS, Gershwin ME, Wick G. In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorioallantoic membrane assay. Arthritis Rheum 2003;48:2605-2614.
18. Kuwana M, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Defective vasculogenesis in systemic sclerosis. Lancet 2004;364:603-610.
19. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994;21:1268-1276.
20. Shi-Wen X, Denton CP, Dashwood MR, Holmes MA, Bou-Charios G, Pearson JD, Black CM, Abraham DJ. Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. J Invest Dermatol 2001;116:417-425.
21. Xu SW, Denton CP, Dashwood MR, Abraham DJ, Black CM. Endothelin-1 regulation of intercellular adhesion molecule-1 expression in normal and sclerodermal fibroblasts. J Cardiovasc Pharmacol 1998;31(Suppl 1):S545-S547.
22. Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, Katamani N. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004;50:216-226.
23. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor -β expression in rat glomerular masangial cells. J Clin Invest 1994;93:2431-2437.
24. Prescot RJ, Freemont AJ, Jones CJP, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992; 166:255-263.
25. Kalogirou A, Gelou E, Zafiriou E, Mountantonakis S, Sakkas LI. Early T cell activation antigen in skin lesions in systemic sclerosis. Ann Rheum Dis 2003;62(Suppl 1): 104.
26. Black C, Dieppe PK, Huckisson T. Regressive systemic sclerosis. Ann Rheum Dis 1986;45:384-388.
27. Sakkas LI, Tourtellotte C, Myer A, Berney S, Platsoucas CD. Increased levels of alternatively spliced interleukin 4 (IL-4δ2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin Diagn Lab Immunol 1999;6:660-664.
28. Arinobu Y, Atamas SP, Otsuka T, Niiro H, Yamaoka K, Mitsuyasu H, Niho Y, Hamasaki N, White B, Izuhara K. Antagonistic effects of an alternative splice variant of human IL-4, IL-4delta2, on IL-4 activities in human monocytes and B cells. Cell Immunol 1999;191:161-167.
29. Kurasawa K, Hirose K, Sano H, Endo H, Shinkai H, Nawata Y, Takabayashi K, Iwamoto I. Increased IL-17 production in patients with systemic sclerosis. Arthritis Rheum 2000;43:2455-2463.
30. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Goldstein P, Banchereau J, Lebecque S. T cell interleukin-17 induces stromal cells to produce pro-inflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-2603.
31. Fukasawa C, Kawaguchi Y, Harigai M, Sugiura T, Takagi K, Kawamoto M, Hara M, Kamatani N. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): Role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003;33:2792-2800.
32. Chizzolini C, Parel Y, De Luca C, Tyndall A, Akesson A, Scheja A, Dayer JM. Systemic sclerosis Th2 cells inhibit collagen production by dermal fibroblasts via membrane-associated tumor necrosis factor alpha. Arthritis Rheum 2003;48:2593-2604.
33. Hasegawa M, Sato S, Takehara K. Augmented production of transforming growth factor-beta by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Arch Dermatol Res 2004;296:89-93.
34. Sato S, Fujimoto M, Hasegawa M, Takehara K. Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naïve B cells and diminished but activated memory B cells. Arthritis Rheum 2004;50:1918-1927.
35. Kuwana M, Medsger TA, Jr, Wright TM. T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis. J Immunol 1995;155:2703-2714.
36. Saito E, Fujimoto M, Hasegawa M, Komura K, Hamaguchi Y, Kaburagi Y, Nagaoka T, Takehara K, Tedder TF, Sato A. CD 19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002;109:1453-1462.
37. Sakkas LI, Xu B, Artlett CA, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal, T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002;168:3649-3659.
38. Bell SA, Faust H, Mittermuller J, Kolb HJ, Meurer M. Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: Clinical correlation and histocompatibility locus antigen association. Br J Dermatol 1996;134:848-854.
39. Arlett C, Smith BR, Jimenez SA. New prespectives on the etiology of systemic sclerosis. N Engl J Med 1998;338:1186-1189.
40. Evans PC, Lambert N, Maloney S, Furst DE, Moore JM, Nelson JL. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 1999;93:2033-2037.
41. Scaletti C, Vultaggio A, Bonifacio S, Emmi L, Torricelli F, Maggi E, Romagnani S, Piccinni MP. Th2-oriented profile of male offspring T cells present in women with systemic sclerosis and reactive with maternal major histocompatibility complex antigens. Arthritis Rheum 2002;46:445-450.
42. Veerarghavan S, Renzoni EA, Jeal H, Jones M, Hammer J, Wells AU, Black CM, Welsh KI, Du Bois RM. Mapping of immunodominant T cell epitopes of the protein topoisomerase I. Ann Rheum Dis 2004;63:982-987.
43. Hu PQ, Fertig N, Medger Jr, TA, Wright TM. Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis. J Immunol 2004; 173:2834-2841.
44. Pandey JP, LeRoy EC. Human cytomegalovirus and the vasculopathies of autoimmune diseases (especially scleroderma), allograft rejection and coronary restenosis. Arthritis Rheum 1998;41:10-15.
45. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte L, Landzberg M, Simonneau G. Bosentan therapy for pulmonary arterial hypertention. N Engl J Med 2002;346:896-903.
46. McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford LJ, Dansey R, Mayes MD, McDonagh KT, Nelson JL, Gooley TA, Holmberg LA, Chen CS, Wener MH, Ryan K, Synderhaus J, Russell K, Rambharose J, Storb R, Furst DA. High-dose immunosuppressive therapy for severe systemic sclerosis: Initial outcomes. Blood 2002;100:1602-1610.
47. Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L, Generini S. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin thickeckness in systemic sclerosis: An open-label trial. Arthritis Rheum 2004;50:1005-1007.
48. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, Ferrara JL, Uberti JP. Treatment of chronic versus host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003;9:505-511.